Shares of dialysis services providers such as DaVita DVA.N and German rival Fresenius Medical Care FMEG.DE declined this week after Novo Nordisk NOVOb.CO’s Ozempic showed early success in a trial to treat kidney failure in diabetes patients.
The Danish drugmaker said late on Tuesday it will stop its kidney outcomes trial almost a year ahead of schedule, based on a recommendation from the independent data monitoring board overseeing the study.
Shares of U.S.-based Baxter International BAX.N, which makes products used by dialysis therapy providers, also fell about 9% to $33.99 premarket.
As of Tuesday’s close, Davita shares were up 22.2% while Baxter shares were down about 27% so far this year, Reuters reports. Read more.
